Biomaterial Database

HIV envelope protein is recognized as an alloantigen by human DR-specific alloreactive T cells. 1992

H Atassi, and M Z Atassi

Department of Biochemistry, Baylor College of Medicine, Houston, Texas 77030.

Recent studies from this laboratory reported the mapping of the full profile of T-cell allorecognition regions of HLA-DR2 beta subunit. The results indicated the presence of an allodeterminant within DR2 beta regions 141-156. In another study, we have shown that this allodeterminant is one of five regions of structural homology between the DR2 beta molecule and the HIV-envelope protein gp120 region 254-268. The fact that gp120 peptide 254-268 is homologous to the allodeterminant within the DR2 beta region 141-156 prompted us to investigate whether synthetic gp120 peptide 254-272 is recognized by human DR2-specific alloreactive T-cell lines. Five human alloreactive T-cell lines were prepared that were specific for the DR2 molecule and did not recognize DR1. These lines mounted in vitro proliferative responses to the allodeterminant peptide DR141-156 and also responded to the DR-similar peptide gp254-272. Removal of the residues 262-272 from the gp120 peptide (i.e., peptide 254-263) resulted in essentially complete loss of its proliferative activity. The effect of deletion of three residues of homology (Val-Val-Ser) at the N terminal (i.e., peptides DR145-156 and gp257-272) was examined. Peptide DR2 beta 145-156 exhibited very low stimulating activity, whereas peptide gp 257-272 did not cause T-cell proliferative responses in any of the alloreactive T-cell lines. The T-cell lines did not respond to unrelated peptide controls, thus further confirming the specificity of these responses. These findings indicate that the virus is recognized as an alloantigen by human alloreactive DR2-specific T cells.

UI	MeSH Term	Description	Entries
D007519	Isoantigens	Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.	Alloantigens,Alloantigen,Isoantigen
D008969	Molecular Sequence Data	Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.	Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446	Peptide Fragments	Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.	Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011498	Protein Precursors		Precursors, Protein
D004306	Dose-Response Relationship, Immunologic	A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.	Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595	Amino Acid Sequence	The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.	Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013602	T-Lymphocytes, Cytotoxic	Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.	Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015497	HIV-1	The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.	Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015686	Gene Products, env	Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesized as protein precursors (POLYPROTEINS) and later cleaved into the final viral envelope glycoproteins by a viral protease.	env Gene Products,env Polyproteins,env Protein,env Antigens,env Glycoproteins,env Polyprotein,Antigens, env,Polyprotein, env,Polyproteins, env